Litchfield Hills Research Comments on ADIL FY2024 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Research analysts at Litchfield Hills Research increased their FY2024 earnings estimates for Adial Pharmaceuticals in a research report issued to clients and investors on Thursday, November 21st. Litchfield Hills Research analyst T. O’neill now anticipates that the company will post earnings of ($1.31) per share for the year, up from their prior estimate of ($1.82). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.33) EPS.

Several other analysts also recently commented on the stock. Rodman & Renshaw began coverage on shares of Adial Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $8.00 price target for the company. RODMAN&RENSHAW upgraded shares of Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th.

Adial Pharmaceuticals Stock Performance

Shares of Adial Pharmaceuticals stock opened at $1.00 on Monday. The company has a fifty day simple moving average of $1.02 and a 200-day simple moving average of $1.10. Adial Pharmaceuticals has a 12-month low of $0.77 and a 12-month high of $4.17.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned approximately 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.